Eric Wittbrodt

About Eric Wittbrodt

Pharmacoepidemiologist and evidence strategy/generation leader for a cardiovascular, renal, and metabolic portfolio with an industry-leading pipeline in a top 10 pharmaceutical company. Experienced manager and mentor of seasoned and high-performing epidemiologists with oversight of study planning, execution, communication strategy, and results narrative dissemination. Real-world evidence and clinical scientist who has:Generated original knowledge in the renal, cardiovascular, amyloidosis, diabetes/metabolism, respiratory, rheumatology, gastrointestinal, and critical care therapeutic areas and in HEOR.Cultivated and maintained external medical and scientific expert relationships in pharmacoepidemiology, diabetes/metabolism, cardiovascular, amyloidosis, gastroenterology, and rheumatologyLed cross-functional study teams for the timely execution of strategically aligned priority RWE work, and experience collaborating with medical, R&D, and commercial functionsDeveloped and delivered training and interactive sessions pertaining to RWE and study updates to internal stakeholdersExperienced speaker who has presented to global internal and external audiences at scientific congresses and invited programsEmbraced a philosophy of a life-long learner with experience, education and credentials in general pharmacotherapeutics with particular emphasis in cardiovascular, renal, metabolism, and amyloidosis, epidemiology (field and pharmaco-epi), evidence strategy, scientific communication, clinical research methods, statistics, health economics and outcomes, field medical, and health care systems (US/UK/CAN/EU). I am passionate about:> Generation of patient-relevant evidence that improves the care of patients with chronic disease to extend and improve the quality of life.> Sharing this evidence to inform guidelines and management pathways through dissemination of impactful narratives > Advocacy sound epidemiological and statistical principles in the design of RWE studies> Integration of relevant clinical expertise into RWE> Development and mentorship of the next generation of pharmacoepidemiologists

Experience

1. Senior Director

   AstraZeneca

   Jul 2019 — Present · Washington, DC, US

   Team leader for 4 FT PhD epidemiologists responsible for development and execution of RWE studies in the CV, CKD, metabolism, and amyloidosis therapy areas.

Education

• Jefferson Health

  Residency in Clinical Pharmacy

  1990 — 1991

• Delta College

  Pre-Pharmacy

  1984 — 1986

• University of the Sciences in Philadelphia

  Residency in Critical Care Pharmacy Practice

  1991 — 1992

• University of Michigan

  PharmD, Pharmacy

  1986 — 1990

• The University of North Carolina at Chapel Hill

  MPH, Public Health

  2009 — 2013

Skills

• Managed Care
• Clinical Development
• Pharmacy
• Health Economics
• Pharmacists
• Pharmaceutical Industry
• Hypertension
• Medical Writing
• Biostatistics
• Epidemiology
• Therapeutic Areas
• Nephrology
• Gastroenterology
• Endocrinology
• Medical Affairs
• Medical Education
• Cardiology
• Rheumatology
• Clinical Trials
• Critical Care
• Clinical Research
• Medicine
• Pharmacokinetics
• Public Health
• Healthcare
• Diabetes
• Oncology
• Infectious Diseases